Genmab A/S(GMAB)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GMAB Genmab A/S

交易中 07-22 11:21:44 EDT

27.57

-0.18

-0.67%

最高27.72	最低27.42	成交量25.07万
今开27.57	昨收27.75	日振幅1.08%
总市值174.94亿	流通市值173.14亿	总股本6.35亿
成交额690.69万	换手率0.04%	流通股本6.28亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"GMAB","market":"US","secType":"STK","nameCN":"Genmab A/S","latestPrice":27.565,"timestamp":1721661684715,"preClose":27.75,"halted":0,"volume":250749,"delay":0,"floatShares":628132725,"shares":634659180,"eps":1.200293,"marketStatus":"交易中","marketStatusCode":2,"change":-0.185,"latestTime":"07-22 11:21:44 EDT","open":27.57,"high":27.72,"low":27.42,"amount":6906925.587572999,"amplitude":0.010811,"askPrice":27.58,"askSize":122,"bidPrice":27.55,"bidSize":541,"shortable":3,"etf":0,"ttmEps":1.200293,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1721678400000},"adr":0,"listingDate":1563422400000,"adjPreClose":27.75,"adrRate":0.1,"preHourTrading":{"tag":"盘前","latestPrice":27.57,"preClose":27.75,"latestTime":"09:29 EDT","volume":6377,"amount":176321.384414,"timestamp":1721654970091},"postHourTrading":{"tag":"盘后","latestPrice":27.75,"preClose":27.75,"latestTime":"18:35 EDT","volume":714402,"amount":19715519.7394,"timestamp":1721428531418},"volumeRatio":0.809743,"impliedVol":0.4447,"impliedVolPercentile":0.6494},"requestUrl":"/m/hq/s/GMAB/wiki","defaultTab":"wiki","newsList":[{"id":"2440547009","title":"美国研究综述-霍尼韦尔国际公司、Stericycle、目标公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2440547009","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440547009?lang=zh_cn&edition=full","pubTime":"2024-06-04 15:29","pubTimestamp":1717486180,"startTime":"0","endTime":"0","summary":"    路透6月4日 - 华尔街证券分析师周二调整了对霍尼韦尔国际公司、Stericycle 和目标公司等几家美国上市公司的评级和目标价。要闻             * Brixmor Property Group Inc   ：高盛将该公司列入其在美上市公司信用评级名单              * 霍尼韦尔国际公司  ：加拿大皇家银行将目标价从222美元下调至218美元              * 西蒙地产集团  ：高盛将其股票从美国定罪名单中删除              * Stericycle Inc   ：加拿大皇家银行将其评级从 \"跑赢大盘 \"下调至 \"行业表现\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR","BK4539","BK4082","BK4187","BWMN","HHH","SRCL","TGT","HUM","SGC","S","CLSK","LU1621768115.EUR","BK4088","LU2286300806.USD","GPCR","BK4155","LU1621767810.EUR","CMCO","AGIO","HON","SPG","GTLB","BK4154","BA","SG9999014013.SGD","BK4532","SRE","ENPH","LU0823414478.USD","SO","EW","IE00BMG7P587.USD","GMAB","ZS","QCOM","LU1267930227.SGD","BRX","TOL","FWONK","BK4080","MARA","FSLR","EQT","TER","LU1621767737.EUR","IE00BMG7P694.USD","RIOT"],"gpt_icon":0},{"id":"2440470047","title":"美国研究综述-霍尼韦尔国际公司、Stericycle、目标公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2440470047","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440470047?lang=zh_cn&edition=full","pubTime":"2024-06-04 15:29","pubTimestamp":1717486180,"startTime":"0","endTime":"0","summary":"    路透6月4日 - 华尔街证券分析师周二调整了对霍尼韦尔国际公司、Stericycle 和目标公司等几家美国上市公司的评级和目标价。要闻             * Brixmor Property Group Inc   ：高盛将该公司列入其在美上市公司信用评级名单              * 霍尼韦尔国际公司  ：加拿大皇家银行将目标价从222美元下调至218美元              * 西蒙地产集团  ：高盛将其股票从美国定罪名单中删除              * Stericycle Inc   ：加拿大皇家银行将其评级从 \"跑赢大盘 \"下调至 \"行业表现\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGT","SO","MARA","SPG","TER","TOL","BK4082","BWMN","LU0823414478.USD","CMCO","GMAB","BK4088","BK4080","SRCL","AGIO","ARWR","EW","SG9999014013.SGD","LU1621767737.EUR","ENPH","LU2286300806.USD","BK4154","FWONK","BK4187","BK4532","GPCR","GTLB","IE00BMG7P587.USD","LU1621767810.EUR","QCOM","RIOT","EQT","CLSK","BK4539","BA","ZS","BRX","HHH","SGC","S","BK4155","LU1267930227.SGD","FSLR","LU1621768115.EUR","HON","SRE","IE00BMG7P694.USD","HUM"],"gpt_icon":0},{"id":"2437003026","title":"Genmab As盘中异动 早盘急速跳水5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2437003026","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437003026?lang=zh_cn&edition=full","pubTime":"2024-05-24 21:30","pubTimestamp":1716557440,"startTime":"0","endTime":"0","summary":"北京时间2024年05月24日21时30分，Genmab As股票出现波动，股价大幅跳水5.03%。Genmab As股票所在的生物技术行业中，整体涨幅为0.05%。Genmab As公司简介：Genmab是一家总部位于哥本哈根的生物技术公司，专门从事用于治疗癌症的抗体疗法。Genmab的专有抗体技术包括DuoBody、HexaBody、DuoHexaBody和HexElect。强生公司与Genmab合作创建了Darzalex，它被认为是多发性骨髓瘤的标准治疗，是Genmab的主导产品。Genmab有几种针对其他肿瘤适应症的候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240524213040af8a2b93&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240524213040af8a2b93&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GMAB"],"gpt_icon":0},{"id":"2432977034","title":"Genmab As盘中异动 早盘大幅上涨7.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2432977034","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432977034?lang=zh_cn&edition=full","pubTime":"2024-05-03 21:31","pubTimestamp":1714743092,"startTime":"0","endTime":"0","summary":"北京时间2024年05月03日21时31分，Genmab As股票出现波动，股价大幅拉升7.72%。Genmab As股票所在的生物技术行业中，整体跌幅为0.50%。Genmab As公司简介：Genmab是一家总部位于哥本哈根的生物技术公司，专门从事用于治疗癌症的抗体疗法。Genmab的专有抗体技术包括DuoBody、HexaBody、DuoHexaBody和HexElect。Genmab有几种针对其他肿瘤适应症的候选药物。该信息摘要如下：HC Wainwright & Co.：重申Genmab评级，由买入调整至买入评级, 目标价50.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405032131328b707edc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405032131328b707edc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VAXX","GMAB","BK4139"],"gpt_icon":0},{"id":"2431531691","title":"HC Wainwright & Co.：重申Genmab(GMAB.US)评级，由买入调整至买入评级, 目标价50.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2431531691","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431531691?lang=zh_cn&edition=full","pubTime":"2024-04-30 18:35","pubTimestamp":1714473323,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：重申Genmab(GMAB.US)评级，由买入调整至买入评级, 目标价50.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043018352687c371b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043018352687c371b1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GMAB"],"gpt_icon":0},{"id":"2424893449","title":"Genmab(GMAB.US)斥资18亿美元全现金收购临床阶段生物技术公司ProfoundBio","url":"https://stock-news.laohu8.com/highlight/detail?id=2424893449","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2424893449?lang=zh_cn&edition=full","pubTime":"2024-04-03 16:45","pubTimestamp":1712133950,"startTime":"0","endTime":"0","summary":"智通财经APP获悉， Genmab周三表示，将以18亿美元的全现金收购私人控股的临床阶段生物技术公司ProfoundBio。这笔交易将使Genmab获得包括rinatabart sesutecan 在内的三种临床候选药物的全球权利，以及ProfoundBio的新型ADC技术平台。该交易有望增强Genmab的中后期临床产品线，并增强其癌症治疗能力。由于这笔交易，Genmab的运营费用预计将升至124亿至134亿丹麦克朗这一指引区间的上限，主要是因为对ProfoundBio临床项目的额外研发投资。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1098440.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","GMAB"],"gpt_icon":0},{"id":"2416628173","title":"Genmab As盘中异动 早盘快速上涨5.04%报29.17美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2416628173","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2416628173?lang=zh_cn&edition=full","pubTime":"2024-03-01 23:46","pubTimestamp":1709308017,"startTime":"0","endTime":"0","summary":"北京时间2024年03月01日23时46分，Genmab As股票出现异动，股价急速拉升5.04%。截至发稿，该股报29.17美元/股，成交量12.9729万股，换手率0.02%，振幅2.07%。Genmab As股票所在的生物技术行业中，整体涨幅为2.23%。Genmab As公司简介：Genmab 是一家总部位于哥本哈根的生物技术公司，专门从事治疗癌症的抗体疗法。Genmab 的专有抗体技术是 DuoBody、HexaBody、DuoHexaBody 和 HexElect。强生与 Genmab 合作创建了 Darzalex，它被视为多发性骨髓瘤的护理标准，是 Genmab 的主导产品。Genmab有几个针对其他肿瘤适应症的候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240301234658861da976&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240301234658861da976&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GMAB","BK4139"],"gpt_icon":0},{"id":"2415379854","title":"Genmab As盘中异动 早盘快速下挫5.09%报27.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2415379854","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2415379854?lang=zh_cn&edition=full","pubTime":"2024-02-28 23:42","pubTimestamp":1709134926,"startTime":"0","endTime":"0","summary":"北京时间2024年02月28日23时42分，Genmab As股票出现波动，股价快速跳水5.09%。截至发稿，该股报27.57美元/股，成交量14.0358万股，换手率0.02%，振幅2.55%。Genmab As股票所在的生物技术行业中，整体跌幅为0.34%。Genmab As公司简介：Genmab 是一家总部位于哥本哈根的生物技术公司，专门从事治疗癌症的抗体疗法。Genmab 的专有抗体技术是 DuoBody、HexaBody、DuoHexaBody 和 HexElect。强生与 Genmab 合作创建了 Darzalex，它被视为多发性骨髓瘤的护理标准，是 Genmab 的主导产品。Genmab有几个针对其他肿瘤适应症的候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240228234207861d9acf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240228234207861d9acf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GMAB"],"gpt_icon":0},{"id":"2412609045","title":"Genmab As2023财年实现净利润6.31亿美元，同比减少19.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2412609045","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2412609045?lang=zh_cn&edition=full","pubTime":"2024-02-18 00:20","pubTimestamp":1708186852,"startTime":"0","endTime":"0","summary":"12月31日，Genmab As公布财报，公告显示公司2023财年净利润为6.31亿美元，同比减少19.10%；其中营业收入为23.90亿美元，同比增加15.91%，每股基本收益为0.97美元。从资产负债表来看，Genmab As总负债5.45亿美元，其中短期债务13.34百万美元，资产负债比为9.60，流动比率为13.35。机构评级：截至2023年12月31日，当前有22家机构对Genmab As目标价做出预测，其中目标均价为39.11美元，其中最低目标价为28.00美元，最高目标价为54.00美元。Genmab有几个针对其他肿瘤适应症的候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240218002054819630d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240218002054819630d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GMAB"],"gpt_icon":0},{"id":"2411589808","title":"Genmab As盘中异动 临近午盘大幅拉升5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2411589808","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2411589808?lang=zh_cn&edition=full","pubTime":"2024-02-15 00:35","pubTimestamp":1707928515,"startTime":"0","endTime":"0","summary":"北京时间2024年02月15日00时35分，Genmab As股票出现波动，股价大幅上涨5.07%。Genmab As股票所在的生物技术行业中，整体涨幅为0.66%。Genmab As公司简介：Genmab 是一家总部位于哥本哈根的生物技术公司，专门从事治疗癌症的抗体疗法。Genmab 的专有抗体技术是 DuoBody、HexaBody、DuoHexaBody 和 HexElect。强生与 Genmab 合作创建了 Darzalex，它被视为多发性骨髓瘤的护理标准，是 Genmab 的主导产品。Genmab有几个针对其他肿瘤适应症的候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240215003515861d53fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240215003515861d53fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GMAB"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genmab.com","stockEarnings":[{"period":"1week","weight":0.0259},{"period":"1month","weight":0.0756},{"period":"3month","weight":-0.0331},{"period":"6month","weight":-0.0411},{"period":"1year","weight":-0.3305},{"period":"ytd","weight":-0.1285}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0009},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.138},{"period":"1year","weight":0.2141},{"period":"ytd","weight":0.155}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Genmab A/S于1998年6月11日注册成立。他们是一家国际生物技术公司，专门从事抗体治疗癌症和其他疾病的治疗。他们的核心目的是通过创造和开发创新的抗体产品来改善患者的生活。公司的愿景是通过在2025年推出自己的专利产品来改变癌症治疗方法，并推进其分化和耐受良好的抗体管道。他们正在建设和扩展他们的后期开发和商业能力，以便他们将来可以将他们的专有产品推向市场。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.066457},{"month":2,"riseRate":0.2,"avgChangeRate":-0.043592},{"month":3,"riseRate":0.6,"avgChangeRate":0.012635},{"month":4,"riseRate":0.6,"avgChangeRate":0.05109},{"month":5,"riseRate":0.6,"avgChangeRate":0.037692},{"month":6,"riseRate":0.6,"avgChangeRate":0.010399},{"month":7,"riseRate":1,"avgChangeRate":0.080236},{"month":8,"riseRate":0.6,"avgChangeRate":0.038504},{"month":9,"riseRate":0,"avgChangeRate":-0.057551},{"month":10,"riseRate":0.6,"avgChangeRate":0.004639},{"month":11,"riseRate":0.8,"avgChangeRate":0.080529},{"month":12,"riseRate":0.6,"avgChangeRate":-0.009591}],"exchange":"NASDAQ","name":"Genmab A/S","nameEN":"Genmab A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Genmab A/S(GMAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Genmab A/S(GMAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Genmab A/S,GMAB,Genmab A/S股票,Genmab A/S股票老虎,Genmab A/S股票老虎国际,Genmab A/S行情,Genmab A/S股票行情,Genmab A/S股价,Genmab A/S股市,Genmab A/S股票价格,Genmab A/S股票交易,Genmab A/S股票购买,Genmab A/S股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Genmab A/S(GMAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Genmab A/S(GMAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况